Alnylam Pharmaceuticals (NASDAQ:ALNY) reported quarterly earnings of $1.99 per share which beat the analyst consensus estimate of $0.93 by 113.98 percent. This is a 586.21 percent increase over earnings of $0.29 per share from the same period last year. The company reported quarterly sales of $1.167 billion which beat the analyst consensus estimate of $1.114 billion by 4.79 percent. This is a 96.40 percent increase over sales of $594.189 million the same period last year.